ADMA Biologics, Inc.
ADMA
$17.10
-$0.20-1.16%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 500.55% | 5,774.29% | 800.00% | 398.49% | 186.34% |
| Total Depreciation and Amortization | -5.39% | -6.10% | -3.44% | 0.62% | 5.45% |
| Total Amortization of Deferred Charges | -56.77% | -62.36% | -63.34% | -40.16% | -28.34% |
| Total Other Non-Cash Items | -260.66% | -275.17% | -291.68% | 275.74% | 290.82% |
| Change in Net Operating Assets | -859.48% | -129.58% | -83.14% | -108.72% | 59.33% |
| Cash from Operations | 5.07% | 375.08% | 1,248.55% | 631.98% | 276.16% |
| Capital Expenditure | -71.76% | -104.52% | -72.42% | 8.96% | 35.98% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 69.66% | -56.89% | -66.19% | -- | -- |
| Cash from Investing | -61.01% | -102.54% | -72.15% | 1.23% | 30.72% |
| Total Debt Issued | -77.78% | -- | -- | -- | -- |
| Total Debt Repaid | 43.25% | 62.17% | 62.17% | -763,402.02% | -467,702.36% |
| Issuance of Common Stock | 316.62% | 207.83% | 578.80% | -89.29% | -96.95% |
| Repurchase of Common Stock | -174.91% | -199.08% | -251.31% | -48.58% | -10.53% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 89.06% | 94.53% | 94.53% | -15,076,900.00% | -3,625.48% |
| Cash from Financing | -57.40% | -60.82% | -49.53% | -205.61% | -165.68% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -92.07% | 210.14% | 247.27% | -68.03% | 154.81% |